| CTNT 0.1608 -5.80% | ZSPC 0.0871 21.48% | ONFO 1.5 124.89% | MYSE 3.3 129.17% | NVDA 198.35 -0.26% | BITO 10.35 0.49% | TZA 5.43 -0.46% | TSLL 13.07 -1.73% | INTC 68.5 5.48% | CAPS 0.5345 -9.25% | HUBC 0.1833 -29.50% | DVLT 0.8375 19.63% | SOXS 20.28 -3.13% | TQQQ 56.43 1.40% | QBTS 21.505 3.34% | AGAE 0.5219 10.57% | HIMS 26.99 11.12% | IONQ 44.68 3.31% | DGNX 0.5556 -0.79% | GRAB 4.02 2.55% | SNAP 6.02 -0.33% | SOFI 19.03 1.28% | SMR 11.41 -2.56% | TSLA 388.9 -0.78% | ITP 0.2 -3.57% | BMNG 1.53 0.66% | SOXL 88.37 2.80% | AMD 278.26 7.80% | RGTI 19.45 1.78% | OPEN 5.27 9.34% | MDCX 0.3003 -0.60% | PLUG 2.86 -2.39% | MARA 11.55 10.32% | NVD 5.81 0.69% | AAL 12.27 0.82% | SQQQ 58.61 -1.40% | IMMP 0.5796 6.54% | HOOD 86.85 -0.54% | ONDS 10.2 1.69% | NVTS 12.37 20.57% | RMSG 2.55 42.46% | BYND 0.782 4.11% | NOK 10.29 3.00% | NFLX 107.79 0.07% | ORCL 178.46 5.09% | SPY 701.66 0.25% | SOUN 7.7 -1.91% | AAPL 263.4 -1.14% | PBM 5.87 103.82% | PLTR 142.76 0.43%

Barclays Initiates Xencor At Underweight, Sees Limited Upside From Pipeline

Barclays initiated coverage of Xencor Inc. (NASDAQ: XNCR) with an Underweight rating and a $6.00 price target.

The firm acknowledged Xencor’s history as an innovator in antibody technology and its royalty-generating partnerships on commercialized drugs such as AstraZeneca’s Ultomiris and Incyte’s Monjuvi/Minjuvi. These collaborations have supported a steady revenue stream and a strong balance sheet.

However, analysts expressed disappointment in the company’s internal pipeline, which they said had failed to generate sufficient valuation upside beyond its royalty base.

Xencor is expected to release early dose-escalation data later this year for its lead oncology program, XmAb819, in clear cell renal cell carcinoma. Barclays noted the results would likely be too preliminary to have a meaningful impact on the stock.

Published on: September 17, 2025